Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Key PointsEli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026.
Key PointsEli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026.
BELLINGS Intelligence Score: 8
Why it matters
This is a routine competitive analysis article about Eli Lilly's market position relative to Amylyx, with no direct impact on credit markets or financing conditions.